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Introduction
In traditional Ayurvedic Indian medicine, preparations of Mucuna pruriens seeds (fig. 1) are used in the treatment 
of Parkinson’s disease (PD). It has been suggested that Mucuna preparations may posses some clinical 
advantages over conventional, synthetic L-DOPA/carbidopa preparations, including a rapid onset of action and 
longer on time without concomitant increase in dyskinesias (Katzenschlager et al. 2004, Kasture et al. 2009, 
Lieu et al. 2010). Alcoholic extracts of MP seeds are rich in L-DOPA, but other, as yet unknown compounds 
may contribute to its therapeutic effects.
Objectives
In 6-hydroxydopamine (6-OHDA) lesioned rats we determined:
1. Therapeutically effective doses of a methanol extract of Mucuna pruriens seeds and of (synthetic) L-DOPA 
without additives. 
2. Abnormal involuntary movements (AIMs) during chronic treatment at therapeutically effective doses.
3. Dose-dependent effects of Mucuna extract and L-DOPA in the presence of benserazide (peripheral 
decarboxylase inhibitor).
4. Effects of  a Mucuna preparation lacking L-DOPA.
Results
Materials and Methods
Twentyfour 6-hydroxydopamine (6-OHDA) lesioned rats were used (Sprague 
Dawley, males; 8 µg 6-OHDA free base in 2 µl saline, 0.1% ascorbic acid 
stereotaxically injected into left medial forebrain bundle), all displaying 
significant contralateral forelimb akinesia and amphetamine-induced rotations 
2-3 weeks postsurgery.
Ten rats were assigned to a chronic ”dose-finding” study (series M1, two 
periods of 4 weeks treatment) and 14 rats assigned to a comparative study of 
therapeutic and adverse effects of chronic Mucuna versus L-DOPA treatments 
without additives (series M2-D2, 4 daily injections in week 1,  5 injections in 
week 2 and 7 injections in week 3). 
After a wash-out period of 4 weeks the latter group of 14 rats was used to 
study effects of Mucuna and L-DOPA in the presence of benserazide and of 
Mucuna extract lacking L-DOPA. 
Forelimb akinesia, therapeutic and adverse effects (i.e. abnormal involuntary 
movements, AIMs) of Mucuna or L-DOPA treatments were assessed using 
the cylinder test, recorded on video and rated on a scale from 0-6 (Lundblad 
et al. 2002). 
Mucuna extracts containing ca. 20% L-DOPA (dry weight extract) were 
prepared and the chemical profiles of different batches were checked by HPLC 
and mass spectrometry to ensure reproducible quality. A Mucuna extract 
lacking the major constituent L-DOPA was prepared by preparative HPLC. 
Mucuna or L-DOPA preparations were solubilized in saline, 1% ascorbic acid 
and administered ip in a volume  up to 12.5 ml/kg. Benserazide was used at 
a dose of 15 mg/kg. 
Rats were killed and brains dissected one week after the last Mucuna or L-DOPA 
injection. Dopamine and 5-hydroxytryptamine (5-HT) levels in ipsilateral 
and contralateral striatum were determined by HPLC with electrochemical 
detection (Gramsbergen et al. 2002).
Figure 1.
Seeds and pods of Mucuna pruriens
Conclusions
• Chronic Mucuna treatments induced a sustained motor improvement that took days to build up and lasted 
for 3-4 days after cessation of treatment, i.e. similar to the long duration response of L-DOPA treatment. 
Determination of the lowest, therapeutically effective doses required therefore repeated dosing. 
•	Mucuna extract was more effective than (synthethic) L-DOPA at equivalent L-DOPA doses of 12.5-25 mg/kg ip. 
However, chronic treatment with these doses of Mucuna extract caused also more severe AIMs (predominantly 
limbic, but also axial and orofacial dyskinesias) than L-DOPA alone. 
• Co-treatments with benserazide in Mucuna or L-DOPA-sensitized rats, did not reveal differences in therapeutic 
or adverse effects of Mucuna or L-DOPA.  
•	Mucuna extract lacking L-DOPA did not show any therapeutic effect. 
This study in 6-OHDA lesioned rats did not reveal clinical benefits of Mucuna treatment over conventional 
L-DOPA therapy.
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Figure 2.
Reversal of contralateral forelimb akinesia following increasing doses of Mucuna extract (3-4 
injections per week during 4 weeks, cylindertest 40-50 min. after dosing). Doses equivalent 
to 12 and 25 mg DOPA/kg i.p. (60-125 mg extract/kg) were not effective in week 2 and 3, 
but appeared effective after repeated (higher) dosing in week 4. **p<0.01. One-way ANOVA, 
Dunnett’s multiple comparison test versus baseline (0). Series M1, N=10 rats. 
Figure 5.
Dopamine levels in ipsilateral and contralateral striatum. Contralateral levels were similar in treatment groups. Ipsilateral (lesioned) levels in M1 
group slightly higher than M2 and D2 groups. One-way ANOVA, *p<0.05 Tukey’s multiple comparison test. N=10 for M1, N=7 for M2 and D2.
Figure 3.
Reversal of forelimb akinesia (therapeutic effect) and AIMs (adverse effects) by chronic 
Mucuna extract treatment at DOPA doses of 12.5 mg/kg (week 1+2, blue), 20 mg/kg 
(week 3+4, dark blue) and 25 mg/kg (day 26, pink). Baseline akinesia is scored at the 
start of the week (1.0, 2.0, 3.0, 4.0, white). Mucuna effects are scored for 2 or 3 days per 
week. *p<0.05 **p<0.01 ***p<0.001, One way ANOVA, Dunnett’s multiple comparison 
tests versus baselines (0). Series M1, N=10 rats.
Figure 9.
Reversal of forelimb akinesia (therapeutic effect) and AIMs (adverse effects) by combined Mu-
cuna + benserazide or (synthetic) L-DOPA + benserazide treatments. Equivalent DOPA doses of 
3, 4.5 and 6 mg/kg i.p. were equally effective and AIMs scores were high. Two-way ANOVA: no 
differences between Mucuna or L-DOPA groups. One-way ANOVA: significant effects for each 
treatment, *p<0.05, ***p<0.01 Dunnett’s multiple comparison test versus baseline (0). Series M2 
and D2,  N=7 vs N=7.
Figure 10.
Rotational behavior following combined Mucuna+benserazide or L-DOPA+ 
benserazide treatments. No significant differences between treatment groups. 
Series M2 and D2, N=7 vs N=7.
Figure 6.
Reversal of forelimb akinesia (therapeutic effect) and AIMs (adverse effects) by chronic Mucuna 
extract and (synthetic) L-DOPA treatments at equivalent DOPA doses of 12.5 mg/kg (week 1), 
20 mg/kg (week 2-3) and 25 mg/kg (day 19-21). Two-way ANOVA: p<0.05 effect of treatment, 
p<0.001 effect of time. Series M2 and D2,  N=7 vs N=7.
Figure 7
Long duration response following chronic Mucuna or L-DOPA treatments (last 
dose 25 mg/kg i.p.). Two-way ANOVA: no significant difference between treat-
ments. *p<0.05 **p<0.01, One way ANOVA, Tukey’s multiple comparison tests 
versus day of drug treatment. Series M2 and D2,  N=7 vs N=7.
Figure 8.
Mucuna extract without L-DOPA (100 mg dry extract/kg ip) did not improve 
contralateral forelimb use (i.e. no therapeutic effect). Series M2 and D2, 
N=7 vs N=7.
Figure 4.
Amphetamine-induced rotations (total of 2 hours recording) prior to Mucuna or L-DOPA 
treatments. No differences between experimental groups. N=10 for M1, N=7 for M2 and 
D2.
